The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.


AZN ASTRAZENECA PLC ORD SHS $0.25

ASTRAZENECA  Currency  GBX  Premium Equity Commercial Companies



 Page 11 of 11

| Previous | 11 |

Time/Date Code Headline Source Impact
07:00 22-Jan-2014 AZN Xigduo approved in EU for type 2 diabetes RNS -0.68% Down
10:42 17-Jan-2014 AZN Replacement re block listing application RNS +3.36% Up
07:00 14-Jan-2014 AZN AstraZeneca provides strategy update at JP Morgan RNS +6.97% Up
07:00 13-Jan-2014 AZN US FDA APPROVES FARXIGAT (DAPAGLIFLOZIN) RNS +7.05% Up
07:00 09-Jan-2014 AZN US FDA Approval of Farxiga (dapagliflozin) RNS +5.16% Up
16:00 02-Jan-2014 AZN Total Voting Rights RNS -0.30% Down
07:13 27-Dec-2013 AZN AZ and Shionogi extend Crestor agreement RNS -0.71% Down
14:00 19-Dec-2013 AZN Director/PDMR Shareholding RNS +1.33% Up
07:50 19-Dec-2013 AZN AZ to acquire BMS share of diabetes assets RNS +1.33% Up
18:13 17-Dec-2013 AZN STATEMENT ON ESOMEPRAZOLE STRONTIUM LAUNCH IN US RNS +2.57% Up
07:14 13-Dec-2013 AZN Top Line Results From Phase III Study of Lesinurad RNS +2.79% Up
07:00 13-Dec-2013 AZN FDA Advisory Committee Recommends Dapagliflozin RNS +2.79% Up
07:00 12-Dec-2013 AZN FDA Advisory Committee Votes on Metreleptin RNS +2.56% Up
07:00 06-Dec-2013 AZN European Commission Approves Fluenz Tetra RNS -0.60% Down
15:00 02-Dec-2013 AZN Blocklisting Interim Review RNS +0.55% Up
13:00 02-Dec-2013 AZN Total Voting Rights RNS +0.55% Up

 Page 11 of 11

| Previous | 11 |

Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released, including the day of the release of the news
y = instrument's latest 7 closing prices before the news was released

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank " - " next to the line indicating the RNS issue.


ASTRAZENECA share - news analysis

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds